• 1-631-338-8059        

Solid Tumor Sequencing Service

Advanced Solid Tumor Sequencing for Cancer Research - Precision NGS Solutions

Our comprehensive sequencing solutions—spanning whole genome sequencing (WGS), whole exome sequencing (WES), and targeted panel sequencing—are crafted to enhance mutation landscape analyses, target discoveries, and tumour mechanism studies.

  • Comprehensive Technology: Full spectrum coverage with WGS, WES, and Panel sequencing.
  • Sample Versatility: Optimized for FFPE samples, biopsies, and minimal sample volumes.
  • In-depth Insights: Explore clonal evolution and the immune microenvironment in detail.
  • Efficient Publishing: Accelerate support for publishing in high-impact journals.
Request a Quote
Solid Tumor Sequencing Service

Choosing the Right Sequencing Strategy for Solid Tumor Research

CD Genomics offers multiple solid tumor sequencing solutions to support a wide range of research goals. The comparison guide below helps you select the most suitable strategy based on your sample type, detection sensitivity, and analysis needs.

Feature Whole Genome Sequencing (WGS) Whole Exome Sequencing (WES) 523-Gene Targeted Panel
Coverage Base-level across the entire genome ±50 bp flanking exons Deep, focused coverage on specific gene regions
Sequencing Depth 30× (tumor) / 60× (normal) 200× (tumor) / 100× (normal) Avg. 500× (≥1000× in hotspots)
Variant Types SNV, Indel, CNV, SV, MSI SNV, Indel, CNV SNV, Indel, CNV, gene fusions, TMB, MSI
Sample Input ≥50 mg fresh frozen tissue FFPE (DV200 ≥ 30%) Biopsy or low-input DNA (≥10 ng)
Preferred Sample Type Fresh-frozen tissue FFPE (stored ≤8 years) Biopsy, FNA, cfDNA
Detection Sensitivity 5% VAF 1% VAF 0.5% VAF
Key Scientific Benefits Non-coding regulatory region analysis; 3D genome mapping Cost-effective somatic/germline variant co-analysis Ultra-sensitive mutation tracking; rapid turnaround
Ideal Applications Systematic discovery of novel targets; rare SV research Pan-cancer mutation profiling; functional validation Drug resistance mapping; immune microenvironment tracking
Suggested Models High-heterogeneity tumors, chromosomal instability models, organoids Pan-cancer cell lines Drug selection models, PDX
Multi-Omics Integration + Whole-genome methylation + RNA-Seq, epigenetic regulation + Longitudinal liquid biopsy, immune repertoire profiling

Streamlined in 5 Steps: From Sample to Scientific Breakthrough

At CD Genomics, we’ve built a fully standardized workflow for solid tumor sequencing—guiding your project from experimental design to data publication. Every step is supported by expert consultation to ensure high efficiency and uncompromising data reliability.

Overview of solid tumor sequencing workflow: project consultation, sample QC, library construction and NGS, bioinformatics analysis, and data delivery with support.

What You’ll Receive

Our comprehensive deliverables are designed to power your research from discovery to high-impact publication.

Raw Sequencing Data

  • High-quality, journal-ready sequencing output
  • Enables reproducibility and customized downstream analysis

Alignment and Variant Files

  • Reference genome mapping results
  • Includes somatic mutation data: SNVs, Indels, with annotations and functional predictions

Quality Control Report

  • Covers every stage: sample QC, sequencing metrics, and data processing
  • Ensures transparency and data integrity

Bioinformatics Analysis Report

  • Publication-quality visualizations and graphs
  • Highlights key insights: mutation profiles, pathway enrichment, frequency statistics

Summary of Deliverables

Deliverable Format Scientific Value
Raw Sequencing Data FASTQ / BAM Traceable primary data, meets journal archive requirements
Variant Analysis Report VCF / MAF Comprehensive somatic mutation landscape: SNVs, Indels, CNVs, SVs
Visualization Report PDF with figures/tables Ready for manuscript drafting, data-rich and publication-friendly

Sample Submission Requirements

Category Guidelines
Sample Type Extracted genomic DNA or FFPE tissue sections
Purity OD260/280: 1.8–2.0; OD260/230 ≥ 2.0
Concentration ≥ 20 ng/μL
Total Yield ≥ 2 μg
Storage Conditions DNA: Store in TE buffer at 4°C for short-term; FFPE: Low-temperature preferred
Shipping Guidelines DNA: Ship on dry ice; FFPE: Seal, moisture-proof, avoid heat
Degradation Criteria DNA must be intact, no visible degradation (gel image preferred)

Tip: If your sample is degraded, low-concentration, or requires DNA extraction, we offer pre-evaluation and rescue protocols tailored to ensure sequencing success.

Applications of Our Solid Tumor Sequencing Services

CD Genomics offers robust sequencing solutions tailored to the unique challenges of cancer research. Whether you're investigating tumour initiation, resistance mechanisms, or new drug targets, our platforms deliver the high-resolution data you need.

Cancer Driver Gene Discovery

Identify high-impact mutations that drive tumour progression and reveal novel therapeutic targets.

Comprehensive Mutation Profiling

Detect and catalogue SNVs, Indels, CNVs, and structural variants for a complete mutation landscape.

Molecular Subtyping & Stratification

Classify tumours based on genomic signatures to guide personalised research or biomarker studies.

Drug Response & Resistance Mechanism Analysis

Uncover the genetic alterations linked to therapy efficacy and resistance development.

Clonal Evolution & Tumour Heterogeneity

Map subclonal architecture and evolutionary dynamics to better understand disease progression.

Neoantigen Prediction & Tumour Immunogenomics

Integrate mutation data to assess TMB and identify potential neoantigens for immunotherapy research.

Why Choose CD Genomics for Solid Tumor Sequencing?

Selecting the right sequencing partner can directly impact the success of your cancer study. Here's why global researchers trust CD Genomics:

Reliable Data from High-End Platforms

We leverage Illumina NovaSeq and rigorous QC pipelines to deliver accurate, high-depth sequencing—ideal for detecting low-frequency variants and complex tumour genomes.

Flexible Solutions for Diverse Study Needs

Choose from whole-genome (WGS), whole-exome (WES), or 500-gene panel sequencing. Our workflows adapt to discovery, mechanistic, or translational research goals.

Expert Bioinformatics Support

Receive publication-ready reports with detailed variant annotation, TMB scoring, and pathway analysis—accelerating time to results and boosting manuscript quality.

End-to-End Project Guidance

Our team brings years of solid tumour research experience and offers full support from experimental design to data interpretation.

Frequently Asked Questions (FAQ) of Solid Tumor Sequencing

Q1: Can the 500-gene panel detect gene fusions?
Q2: Do I need fresh tumour tissue, or are FFPE samples acceptable?
Q3: What bioinformatics analyses are included?
Q4: I’m not experienced in sequencing study design—can you help?
* For research purposes only, not intended for clinical diagnosis, treatment, or individual health assessments.
PDF Download
* Email Address:

CD Genomics needs the contact information you provide to us in order to contact you about our products and services and other content that may be of interest to you. By clicking below, you consent to the storage and processing of the personal information submitted above by CD Genomcis to provide the content you have requested.

×
  • SUITE 111, 17 Ramsey Road, Shirley, NY 11967, USA
  • 1-631-338-8059
  • 1-631-614-7828
Copyright © 2025 CD Genomics. All rights reserved.
Top
0
Inquiry Basket

We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy

Accept Cookies
x